- Home
- FURY vs KRON Comparison
FURY vs KRON Comparison
Compare FURY & KRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FURY
- KRON
- Stock Information
- Founded
- FURY 2008
- KRON 2017
- Country
- FURY Canada
- KRON United States
- Employees
- FURY N/A
- KRON N/A
- Industry
- FURY Precious Metals
- KRON Medicinal Chemicals and Botanical Products
- Sector
- FURY Basic Materials
- KRON Health Care
- Exchange
- FURY Nasdaq
- KRON Nasdaq
- Market Cap
- FURY 60.5M
- KRON 61.5M
- IPO Year
- FURY N/A
- KRON 2020
- Fundamental
- Price
- FURY $0.40
- KRON $0.85
- Analyst Decision
- FURY Strong Buy
- KRON Buy
- Analyst Count
- FURY 1
- KRON 3
- Target Price
- FURY $1.10
- KRON $1.63
- AVG Volume (30 Days)
- FURY 133.2K
- KRON 165.9K
- Earning Date
- FURY 05-13-2025
- KRON 03-18-2025
- Dividend Yield
- FURY N/A
- KRON N/A
- EPS Growth
- FURY N/A
- KRON N/A
- EPS
- FURY N/A
- KRON N/A
- Revenue
- FURY N/A
- KRON $9,848,000.00
- Revenue This Year
- FURY N/A
- KRON N/A
- Revenue Next Year
- FURY N/A
- KRON N/A
- P/E Ratio
- FURY N/A
- KRON N/A
- Revenue Growth
- FURY N/A
- KRON 56.62
- 52 Week Low
- FURY $0.35
- KRON $0.69
- 52 Week High
- FURY $0.59
- KRON $1.60
- Technical
- Relative Strength Index (RSI)
- FURY 49.92
- KRON 31.82
- Support Level
- FURY $0.39
- KRON $0.82
- Resistance Level
- FURY $0.42
- KRON $0.95
- Average True Range (ATR)
- FURY 0.02
- KRON 0.06
- MACD
- FURY -0.00
- KRON -0.01
- Stochastic Oscillator
- FURY 25.00
- KRON 10.94
About FURY Fury Gold Mines Limited
Fury Gold Mines Ltd is a Canadian-focused exploration and development company strategically positioned in three prolific mining regions: James Bay, Quebec; the Golden Triangle, British Columbia; and the Kitikmeot Region Nunavut. Its projects include Eau Claire, Homestake Ridge, Committee Bay, Eleonore South JV, and Gibson MacQuoid.
About KRON Kronos Bio Inc.
Kronos Bio Inc is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine plan by targeting dysregulated transcription. The company operates in one business segment, the development of biopharmaceutical products.